NL-OMON48072已完成不适用
A study evaluating the pharmacokinetics, safety and tolerability of OP2113 administered intravenously in healthy volunteers and a marketed formulation administered orally - OP2-CS-001 OP2 Drugs
OP2 Drugs0 个研究点目标入组 12 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Healthy male and female subjects aged between 18 and 65 years (inclusive) with
- •a body mass index (BMI) of *18.0 kg/m2 and * 30.0 kg/m2 (inclusive) at
- •Further inclusion criteria can be found in the protocol section 8.4.1
排除标准
- •Relevant prior or ongoing medical condition that, in the Investigator*s
- •opinion, could adversely affect the safety of the subject.
- •History of clinically-significant hypersensitivity to any of the study drugs,
- •excipients or materials used to administer the study medication.
- •Further exclusion criteria can be found in the protocol section 8.4.2
研究者
相似试验
已完成
不适用
A study to evaluate the pharmacokinetics, safety and tolerability after inhalation of MMI-0100 in healthy subjects; MMI-0100 is an investigational drug developed for the treatment of fibrotic indications.Idiopathic pulmonary fibrosisidiopathische fibrosepulmonary diseases.NL-OMON40896Moerae Matrix, Inc48
已完成
不适用
The aim of this study is to compare and evaluate the pharmacokinetic properties and safety of oral administration of test drugEndocrine, nutritional and metabolic diseasesKCT0004026Kyung Dong Pharmaceutical80
进行中（未招募）
不适用
Study to evaluate the safety and pharmacokinetics of ciprofloxacin following inhalation of ciprofloxacin dry powder for inhalation administered to pediatric patients with cystic fibrosis aged 12-17 yearslong term treatment of chronic lung infections caused by Pseudomonas aeruginosa in patients with cystic fibrosisMedDRA version: 8.1Level: LLTClassification code 10011763Term: Cystic fibrosis lungEUCTR2007-002912-24-DEBayer HealthCare AG16
招募中
1 期
A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors-JPRN-jRCT2080225128-6
尚未招募
1 期
Safety and pharmacokinetics of CIGB-552Solid tumorsRPCEC00000196Center for Genetic Engineering and Biotechnology (CIGB)